Clinical Trial

A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label, phase I dose-escalation clinical study to evaluate the safety and preliminary efficacy of CLL1 and CD38 dual-target CAR T cell injection in r/r AML subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-11.
Status change: Not Yet Recruiting → Recruiting 2025-05-28
Trial Details
NCT Number NCT06880354
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Collaborators: Gracell Biotechnologies (Shanghai) Co., Ltd., AstraZeneca
Conditions Acute Myeloid Leukemia
Enrollment 37 participants
Start Date 2025-05-22
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-03